The deletion of PD-1 caused the production of autoantibodies and reduction of regulatory T cells, which eventually resulted in cardiomyopathy.[14] In general, the ICIs therapy enhances the release of tumor-specific T cells, but weakens the immune tolerance, finally leading to the activation of self-reactive effector cells and heart tissue damage. Here, PDCD1 is linked to cardiomyopathy.